FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), High Glucose & 25mM HEPES w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), High Glucose & 25mM HEPES w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ DCP-DMEMH-BR1X is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) DMEM High Glucose (4.5 g/L) formulation with 25 mM HEPES buffer, engineered for organ-on-a-chip (OoC), microphysiological systems (MPS), and CO₂-independent or open-top microfluidic platforms. HEPES (25 mM, pKa 7.3 at 37°C) provides robust CO₂-independent pH buffering in a formulation that omits both sodium bicarbonate and phenol red. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• High Glucose (4.5 g/L) — supports neurons, cardiomyocytes, cancer lines, and aerobically active cells
• 25 mM HEPES (pKa 7.3 at 37°C) — robust pH buffering independent of CO₂ tension; sodium bicarbonate and phenol red are not added
• 0.04 µm final nano-filtration — sub-mycoplasma-scale pore size for microfluidic channels below 100 µm
• Quadruple-stage filtration: 0.1 µm Prefiltration I → 0.04 µm Final filtration I → 0.1 µm Prefiltration II → 0.04 µm Final filtration II — Polish
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>), controlled per manufacturing batch
• Ultrapure Type 1 water (18.2 MΩ·cm), ISO 13485:2016 QMS, ISO Class 5 aseptic fill
• Custom pH, salts, glucose, HEPES concentration, and nutrient adjustments available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered DMEM passes mycoplasma-scale particulates, subvisible debris, and fine aggregates that can accumulate in microfluidic channels. Standard DMEM also lacks HEPES buffering, causing pH instability whenever chips are handled outside incubators. FluxMPS™ addresses both conditions simultaneously.

Quadruple-stage filtration system

1. 1

   0.1 µm Prefiltration I

   Large particulate, cell debris and protein aggregate removal; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; ISO Class 5 aseptic fill & finish.

Designed for next-generation cell models

FluxMPS™ DCP-DMEMH-BR1X combines high-glucose energy support with HEPES pH stability — supporting demanding platforms from open-top microfluidic chips and CO₂-free bioreactors to multi-organ body-on-a-chip systems.

Automated Bioreactors & Robotics

HEPES buffering removes CO₂ dependency during automated bioreactor perfusion. An optional 0.01 µm (10 nm) ultra-filtered MPS Grade variant is available on request for robotic liquid handlers where trace particulates cause valve failure.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates from bioreactor media lines
• pH-Stable Automated Delivery: HEPES maintains pH during robotic media exchanges without CO₂ re-equilibration delays
• Extended Perfusion Stability: Consistent high-glucose delivery with stable pH over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

DMEM High Glucose + HEPES is a modification of Basal Medium Eagle (BME) with 4× BME amino acid and vitamin concentrations. 32 ingredients verified per lot with CAS numbers for full raw-material traceability, across three composition tabs (Inorganic Salts, Amino Acids, Vitamins & Others). HEPES (25 mM = 5958 mg/L) is listed in the OTHERS group.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEMH-BR1X compares

FluxMPS™ DCP-DMEMH-BR1X vs. conventional 0.22 µm–filtered DMEM High Glucose formulations.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEMH-BR1X DMEM High Glucose + 25mM HEPES.

Supporting literature

Key peer-reviewed publications supporting Microfluidics Suitable, HEPES-buffered, ultra-filtered DMEM High Glucose in organ-on-a-chip and metabolic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662-1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760-772. doi:10.1038/nbt.2989
3. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314. doi:10.1126/science.123.3191.309
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407-420. doi:10.1038/s41551-019-0497-x
5. Katt ME, et al. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol. 2016;4:12. doi:10.3389/fbioe.2016.00012
6. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119-1129. doi:10.1039/c3ib40049b
7. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588-3598. doi:10.1039/c3lc50217a
8. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446-452. doi:10.1038/nmeth.3832
9. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201-1212. doi:10.1039/c3lc41017j